Clinical trial · Interventional
Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)
Open, Randomized, Multicenter, Randomized Phase II Trial Comparing the Combination of Cetuximab With Oxaliplatin/5-FU/FA Versus the Combination of Cetuximab With Irinotecan/5-FU/FA as Neoadjuvant Treatment in Patients With Non-Resectable Colorectal Liver Metastases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
General Objectives: * To test the feasibility of neoadjuvant treatment with cetuximab/chemotherapy followed by liver resection * To determine the optimal combination (cetuximab/FOLFOX versus cetuximab/FOLFIRI) for further trials in preoperative chemotherapy
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Liver Metastases | Colorectal Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cetuximab | Drug | Cetuximab | ALIAS |
| Cetuximab and FOLFIRI | Drug | — | UNRESOLVED |
| Cetuximab and FOLFOX | Drug | — | UNRESOLVED |
| Liver resection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- 1
- description
- Cetuximab and FOLFIRI
- interventionNames
- Drug: Cetuximab
- Procedure: Liver resection
- Drug: Cetuximab and FOLFIRI
- type
- ACTIVE_COMPARATOR
- label
- 2
- description
- Cetuximab and FOLFOX
- interventionNames
- Drug: Cetuximab
- Procedure: Liver resection
- Drug: Cetuximab and FOLFOX
Primary outcomes (1)
- measure
- Tumor response, defined as partial and complete response according to RECIST (Response Evaluation Criteria in Solid Tumors) - criteria in the intention-to-treat [ITT-] population
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with non-resectable, histologically confirmed, synchronous or metachronous colorectal liver metastases. Patients with non-resectable metastases are defined as; patients with five or more liver metastases; and/or patients with liver metastases that are technically non-resectable (local surgeon in cooperation with local radiologist will define non-resectability on the basis of remaining functional liver tissue, infiltration of all liver veins, infiltration of both liver arteries, both portal branches or both bile ducts). * Patients with simultaneous liver metastases are eligible, if the primary tumor has been resected at least 1 month prior to chemotherapy. * Karnofsky Performance Status ≥ 80 * Informed consent * Adequate bone marrow function, liver and renal function (neutrophils \> 1.5 x 10\^9/l; thrombocytes \> 100 x 10\^9/l; hemoglobin \> 8.0 g/l; bilirubin ≤ 1.5 x upper limit of normal \[ULN\] and not increasing more than 25% within the last 4 weeks; ALAT and ASAT \< 5 x UNL; serum creatinine ≤ 1.5 x UNL) * Age ≥ 18 years Exclusion Criteria: * Any evidence of extrahepatic metastases, lymph node metastases and primary tumor recurrence * Prior chemotherapy (except adjuvant chemotherapy with an interval of ≥ 6 months) * Previous exposure to EGFR (epidermal growth factor receptor)-targeting therapy * Radiotherapy or major abdominal or thoracic surgery (excluding diagnostic biopsy or port implantation) ≤ 4 weeks before study entry * Concurrent systemic immune therapy, chemotherapy, or hormone therapy * Investigational agents or participation in clinical trials within 30 days before start of the treatment in study * Clinically relevant coronary disease or myocardial infarction within 12 months before study entry * Peripheral neuropathy \> CTC grade I * Inflammatory bowel disease * Previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment) * History of severe psychiatric illness * Drug or alcohol abuse * Breast feeding or pregnant women, no effective contraception if risk of conception exists (male and female patients)
References
Publications (2)
- DERIVEDFolprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Kohne CH. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol. 2014 May;25(5):1018-25. doi: 10.1093/annonc/mdu088. Epub 2014 Feb 27. PMID 24585720
- DERIVEDFolprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Kohne CH. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010 Jan;11(1):38-47. doi: 10.1016/S1470-2045(09)70330-4. Epub 2009 Nov 26. PMID 19942479